nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Ribavirin—ENPP1—obesity	0.00663	0.274	CrCbGaD
Regadenoson—Adenosine monophosphate—ACSL1—obesity	0.00388	0.161	CrCbGaD
Regadenoson—Adenosine triphosphate—ACSL1—obesity	0.00336	0.139	CrCbGaD
Regadenoson—Vidarabine—DPP4—obesity	0.00292	0.121	CrCbGaD
Regadenoson—Adenosine—DPP4—obesity	0.00234	0.0967	CrCbGaD
Regadenoson—Nausea—Phendimetrazine—obesity	0.00168	0.00259	CcSEcCtD
Regadenoson—Asthenia—Phentermine—obesity	0.00166	0.00256	CcSEcCtD
Regadenoson—Feeling abnormal—Diethylpropion—obesity	0.00166	0.00256	CcSEcCtD
Regadenoson—Atrioventricular block—Topiramate—obesity	0.00164	0.00253	CcSEcCtD
Regadenoson—Renal failure—Orlistat—obesity	0.00163	0.00251	CcSEcCtD
Regadenoson—Musculoskeletal pain—Topiramate—obesity	0.00161	0.00248	CcSEcCtD
Regadenoson—Urticaria—Diethylpropion—obesity	0.0016	0.00246	CcSEcCtD
Regadenoson—Dizziness—Phenylpropanolamine—obesity	0.0016	0.00246	CcSEcCtD
Regadenoson—Diarrhoea—Phentermine—obesity	0.00158	0.00244	CcSEcCtD
Regadenoson—Acute coronary syndrome—Sibutramine—obesity	0.00158	0.00244	CcSEcCtD
Regadenoson—Abdominal distension—Bupropion—obesity	0.00158	0.00243	CcSEcCtD
Regadenoson—Feeling abnormal—Cimetidine—obesity	0.00158	0.00243	CcSEcCtD
Regadenoson—Renal failure—Sibutramine—obesity	0.00158	0.00243	CcSEcCtD
Regadenoson—Myocardial infarction—Sibutramine—obesity	0.00157	0.00242	CcSEcCtD
Regadenoson—Asthma—Bupropion—obesity	0.00157	0.00242	CcSEcCtD
Regadenoson—Bronchospasm—Bupropion—obesity	0.00154	0.00238	CcSEcCtD
Regadenoson—Depressed level of consciousness—Topiramate—obesity	0.00154	0.00237	CcSEcCtD
Regadenoson—Vomiting—Phenylpropanolamine—obesity	0.00154	0.00237	CcSEcCtD
Regadenoson—Dizziness—Phentermine—obesity	0.00153	0.00236	CcSEcCtD
Regadenoson—Rash—Phenylpropanolamine—obesity	0.00152	0.00235	CcSEcCtD
Regadenoson—Dermatitis—Phenylpropanolamine—obesity	0.00152	0.00235	CcSEcCtD
Regadenoson—Abdominal discomfort—Bupropion—obesity	0.0015	0.00232	CcSEcCtD
Regadenoson—Vomiting—Phentermine—obesity	0.00147	0.00227	CcSEcCtD
Regadenoson—Bradycardia—Sibutramine—obesity	0.00147	0.00226	CcSEcCtD
Regadenoson—Rash—Phentermine—obesity	0.00146	0.00225	CcSEcCtD
Regadenoson—Dermatitis—Phentermine—obesity	0.00146	0.00225	CcSEcCtD
Regadenoson—Headache—Phentermine—obesity	0.00145	0.00223	CcSEcCtD
Regadenoson—Nausea—Phenylpropanolamine—obesity	0.00144	0.00221	CcSEcCtD
Regadenoson—Hypoaesthesia—Sibutramine—obesity	0.00143	0.00221	CcSEcCtD
Regadenoson—Hypersensitivity—Cimetidine—obesity	0.00141	0.00217	CcSEcCtD
Regadenoson—S-Adenosylmethionine—COMT—obesity	0.0014	0.0578	CrCbGaD
Regadenoson—Acute coronary syndrome—Bupropion—obesity	0.00138	0.00213	CcSEcCtD
Regadenoson—Diarrhoea—Diethylpropion—obesity	0.00138	0.00212	CcSEcCtD
Regadenoson—Nausea—Phentermine—obesity	0.00137	0.00212	CcSEcCtD
Regadenoson—Asthenia—Cimetidine—obesity	0.00137	0.00212	CcSEcCtD
Regadenoson—Myocardial infarction—Bupropion—obesity	0.00137	0.00211	CcSEcCtD
Regadenoson—Eye disorder—Sibutramine—obesity	0.00135	0.00207	CcSEcCtD
Regadenoson—Immune system disorder—Orlistat—obesity	0.00134	0.00207	CcSEcCtD
Regadenoson—Tinnitus—Sibutramine—obesity	0.00134	0.00207	CcSEcCtD
Regadenoson—Mediastinal disorder—Orlistat—obesity	0.00134	0.00207	CcSEcCtD
Regadenoson—Dizziness—Diethylpropion—obesity	0.00133	0.00205	CcSEcCtD
Regadenoson—Diarrhoea—Cimetidine—obesity	0.00131	0.00202	CcSEcCtD
Regadenoson—Angiopathy—Sibutramine—obesity	0.00131	0.00201	CcSEcCtD
Regadenoson—Mental disorder—Orlistat—obesity	0.0013	0.00201	CcSEcCtD
Regadenoson—Immune system disorder—Sibutramine—obesity	0.0013	0.00201	CcSEcCtD
Regadenoson—Eye pain—Topiramate—obesity	0.00128	0.00197	CcSEcCtD
Regadenoson—Vomiting—Diethylpropion—obesity	0.00128	0.00197	CcSEcCtD
Regadenoson—Rash—Diethylpropion—obesity	0.00127	0.00196	CcSEcCtD
Regadenoson—Dysgeusia—Orlistat—obesity	0.00127	0.00196	CcSEcCtD
Regadenoson—Dermatitis—Diethylpropion—obesity	0.00127	0.00195	CcSEcCtD
Regadenoson—Dizziness—Cimetidine—obesity	0.00127	0.00195	CcSEcCtD
Regadenoson—Headache—Diethylpropion—obesity	0.00126	0.00194	CcSEcCtD
Regadenoson—Hypoaesthesia—Bupropion—obesity	0.00125	0.00193	CcSEcCtD
Regadenoson—Connective tissue disorder—Bupropion—obesity	0.00123	0.0019	CcSEcCtD
Regadenoson—Dysgeusia—Sibutramine—obesity	0.00123	0.00189	CcSEcCtD
Regadenoson—Vision blurred—Orlistat—obesity	0.00122	0.00188	CcSEcCtD
Regadenoson—Vomiting—Cimetidine—obesity	0.00122	0.00188	CcSEcCtD
Regadenoson—Rash—Cimetidine—obesity	0.00121	0.00186	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—obesity	0.00121	0.0499	CrCbGaD
Regadenoson—Dermatitis—Cimetidine—obesity	0.00121	0.00186	CcSEcCtD
Regadenoson—Ill-defined disorder—Orlistat—obesity	0.0012	0.00185	CcSEcCtD
Regadenoson—Headache—Cimetidine—obesity	0.0012	0.00185	CcSEcCtD
Regadenoson—Nausea—Diethylpropion—obesity	0.00119	0.00184	CcSEcCtD
Regadenoson—Angioedema—Orlistat—obesity	0.00118	0.00182	CcSEcCtD
Regadenoson—Vision blurred—Sibutramine—obesity	0.00118	0.00182	CcSEcCtD
Regadenoson—Tremor—Sibutramine—obesity	0.00117	0.00181	CcSEcCtD
Regadenoson—Eye disorder—Bupropion—obesity	0.00117	0.00181	CcSEcCtD
Regadenoson—Tinnitus—Bupropion—obesity	0.00117	0.0018	CcSEcCtD
Regadenoson—Malaise—Orlistat—obesity	0.00117	0.0018	CcSEcCtD
Regadenoson—Cardiac disorder—Bupropion—obesity	0.00116	0.0018	CcSEcCtD
Regadenoson—Flushing—Bupropion—obesity	0.00116	0.0018	CcSEcCtD
Regadenoson—Ill-defined disorder—Sibutramine—obesity	0.00116	0.00179	CcSEcCtD
Regadenoson—Pain in extremity—Topiramate—obesity	0.00116	0.00178	CcSEcCtD
Regadenoson—Angioedema—Sibutramine—obesity	0.00114	0.00177	CcSEcCtD
Regadenoson—Palpitations—Orlistat—obesity	0.00114	0.00176	CcSEcCtD
Regadenoson—Angiopathy—Bupropion—obesity	0.00114	0.00176	CcSEcCtD
Regadenoson—Nausea—Cimetidine—obesity	0.00114	0.00175	CcSEcCtD
Regadenoson—Immune system disorder—Bupropion—obesity	0.00113	0.00175	CcSEcCtD
Regadenoson—Mediastinal disorder—Bupropion—obesity	0.00113	0.00174	CcSEcCtD
Regadenoson—Malaise—Sibutramine—obesity	0.00113	0.00174	CcSEcCtD
Regadenoson—Cough—Orlistat—obesity	0.00113	0.00174	CcSEcCtD
Regadenoson—Syncope—Sibutramine—obesity	0.00112	0.00173	CcSEcCtD
Regadenoson—Convulsion—Orlistat—obesity	0.00112	0.00173	CcSEcCtD
Regadenoson—Palpitations—Sibutramine—obesity	0.00111	0.00171	CcSEcCtD
Regadenoson—Chest pain—Orlistat—obesity	0.0011	0.0017	CcSEcCtD
Regadenoson—Myalgia—Orlistat—obesity	0.0011	0.0017	CcSEcCtD
Regadenoson—Loss of consciousness—Sibutramine—obesity	0.0011	0.0017	CcSEcCtD
Regadenoson—Mental disorder—Bupropion—obesity	0.0011	0.0017	CcSEcCtD
Regadenoson—Anxiety—Orlistat—obesity	0.0011	0.00169	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.00109	0.00169	CcSEcCtD
Regadenoson—Cough—Sibutramine—obesity	0.00109	0.00169	CcSEcCtD
Regadenoson—Discomfort—Orlistat—obesity	0.00109	0.00168	CcSEcCtD
Regadenoson—Convulsion—Sibutramine—obesity	0.00109	0.00167	CcSEcCtD
Regadenoson—Hypertension—Sibutramine—obesity	0.00108	0.00167	CcSEcCtD
Regadenoson—Dysgeusia—Bupropion—obesity	0.00107	0.00165	CcSEcCtD
Regadenoson—Myalgia—Sibutramine—obesity	0.00107	0.00165	CcSEcCtD
Regadenoson—Chest pain—Sibutramine—obesity	0.00107	0.00165	CcSEcCtD
Regadenoson—Arthralgia—Sibutramine—obesity	0.00107	0.00165	CcSEcCtD
Regadenoson—Anxiety—Sibutramine—obesity	0.00106	0.00164	CcSEcCtD
Regadenoson—Anaphylactic shock—Orlistat—obesity	0.00106	0.00163	CcSEcCtD
Regadenoson—Discomfort—Sibutramine—obesity	0.00105	0.00163	CcSEcCtD
Regadenoson—Nervous system disorder—Orlistat—obesity	0.00104	0.0016	CcSEcCtD
Regadenoson—Vision blurred—Bupropion—obesity	0.00103	0.00159	CcSEcCtD
Regadenoson—Skin disorder—Orlistat—obesity	0.00103	0.00158	CcSEcCtD
Regadenoson—Tremor—Bupropion—obesity	0.00102	0.00158	CcSEcCtD
Regadenoson—Anaphylactic shock—Sibutramine—obesity	0.00102	0.00158	CcSEcCtD
Regadenoson—Hyperhidrosis—Orlistat—obesity	0.00102	0.00158	CcSEcCtD
Regadenoson—Ill-defined disorder—Bupropion—obesity	0.00101	0.00156	CcSEcCtD
Regadenoson—Shock—Sibutramine—obesity	0.00101	0.00155	CcSEcCtD
Regadenoson—Abdominal distension—Topiramate—obesity	0.00101	0.00155	CcSEcCtD
Regadenoson—Asthma—Topiramate—obesity	0.000999	0.00154	CcSEcCtD
Regadenoson—Angioedema—Bupropion—obesity	0.000998	0.00154	CcSEcCtD
Regadenoson—Tachycardia—Sibutramine—obesity	0.000998	0.00154	CcSEcCtD
Regadenoson—Skin disorder—Sibutramine—obesity	0.000993	0.00153	CcSEcCtD
Regadenoson—Hyperhidrosis—Sibutramine—obesity	0.000989	0.00152	CcSEcCtD
Regadenoson—Malaise—Bupropion—obesity	0.000985	0.00152	CcSEcCtD
Regadenoson—Syncope—Bupropion—obesity	0.00098	0.00151	CcSEcCtD
Regadenoson—Angina pectoris—Topiramate—obesity	0.000973	0.0015	CcSEcCtD
Regadenoson—Palpitations—Bupropion—obesity	0.000965	0.00149	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Orlistat—obesity	0.000963	0.00148	CcSEcCtD
Regadenoson—Loss of consciousness—Bupropion—obesity	0.00096	0.00148	CcSEcCtD
Regadenoson—Abdominal discomfort—Topiramate—obesity	0.000957	0.00148	CcSEcCtD
Regadenoson—Insomnia—Orlistat—obesity	0.000956	0.00147	CcSEcCtD
Regadenoson—Hypotension—Sibutramine—obesity	0.000956	0.00147	CcSEcCtD
Regadenoson—Cough—Bupropion—obesity	0.000953	0.00147	CcSEcCtD
Regadenoson—Paraesthesia—Orlistat—obesity	0.000949	0.00146	CcSEcCtD
Regadenoson—Convulsion—Bupropion—obesity	0.000946	0.00146	CcSEcCtD
Regadenoson—Hypertension—Bupropion—obesity	0.000943	0.00145	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Sibutramine—obesity	0.000932	0.00144	CcSEcCtD
Regadenoson—Arthralgia—Bupropion—obesity	0.00093	0.00143	CcSEcCtD
Regadenoson—Chest pain—Bupropion—obesity	0.00093	0.00143	CcSEcCtD
Regadenoson—Myalgia—Bupropion—obesity	0.00093	0.00143	CcSEcCtD
Regadenoson—Anxiety—Bupropion—obesity	0.000927	0.00143	CcSEcCtD
Regadenoson—Cytarabine—SLC22A1—obesity	0.000926	0.0383	CrCbGaD
Regadenoson—Insomnia—Sibutramine—obesity	0.000925	0.00143	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000924	0.00142	CcSEcCtD
Regadenoson—Discomfort—Bupropion—obesity	0.000919	0.00142	CcSEcCtD
Regadenoson—Paraesthesia—Sibutramine—obesity	0.000918	0.00142	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Orlistat—obesity	0.000912	0.00141	CcSEcCtD
Regadenoson—Dyspnoea—Sibutramine—obesity	0.000912	0.00141	CcSEcCtD
Regadenoson—Somnolence—Sibutramine—obesity	0.000909	0.0014	CcSEcCtD
Regadenoson—Pain—Orlistat—obesity	0.000904	0.00139	CcSEcCtD
Regadenoson—Anaphylactic shock—Bupropion—obesity	0.000891	0.00137	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Sibutramine—obesity	0.000883	0.00136	CcSEcCtD
Regadenoson—Shock—Bupropion—obesity	0.000877	0.00135	CcSEcCtD
Regadenoson—Renal failure—Topiramate—obesity	0.000875	0.00135	CcSEcCtD
Regadenoson—Pain—Sibutramine—obesity	0.000874	0.00135	CcSEcCtD
Regadenoson—Nervous system disorder—Bupropion—obesity	0.000874	0.00135	CcSEcCtD
Regadenoson—Feeling abnormal—Orlistat—obesity	0.000871	0.00134	CcSEcCtD
Regadenoson—Tachycardia—Bupropion—obesity	0.00087	0.00134	CcSEcCtD
Regadenoson—Skin disorder—Bupropion—obesity	0.000866	0.00134	CcSEcCtD
Regadenoson—Gastrointestinal pain—Orlistat—obesity	0.000864	0.00133	CcSEcCtD
Regadenoson—Hyperhidrosis—Bupropion—obesity	0.000862	0.00133	CcSEcCtD
Regadenoson—Cladribine—SLC22A1—obesity	0.000852	0.0353	CrCbGaD
Regadenoson—Feeling abnormal—Sibutramine—obesity	0.000843	0.0013	CcSEcCtD
Regadenoson—Urticaria—Orlistat—obesity	0.000839	0.00129	CcSEcCtD
Regadenoson—Gastrointestinal pain—Sibutramine—obesity	0.000836	0.00129	CcSEcCtD
Regadenoson—Abdominal pain—Orlistat—obesity	0.000835	0.00129	CcSEcCtD
Regadenoson—Hypotension—Bupropion—obesity	0.000833	0.00128	CcSEcCtD
Regadenoson—Bradycardia—Topiramate—obesity	0.000814	0.00126	CcSEcCtD
Regadenoson—Urticaria—Sibutramine—obesity	0.000812	0.00125	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Bupropion—obesity	0.000812	0.00125	CcSEcCtD
Regadenoson—Abdominal pain—Sibutramine—obesity	0.000808	0.00125	CcSEcCtD
Regadenoson—Insomnia—Bupropion—obesity	0.000806	0.00124	CcSEcCtD
Regadenoson—Paraesthesia—Bupropion—obesity	0.0008	0.00123	CcSEcCtD
Regadenoson—Hypoaesthesia—Topiramate—obesity	0.000795	0.00123	CcSEcCtD
Regadenoson—Dyspnoea—Bupropion—obesity	0.000795	0.00123	CcSEcCtD
Regadenoson—Somnolence—Bupropion—obesity	0.000793	0.00122	CcSEcCtD
Regadenoson—Connective tissue disorder—Topiramate—obesity	0.000786	0.00121	CcSEcCtD
Regadenoson—Hypersensitivity—Orlistat—obesity	0.000778	0.0012	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Bupropion—obesity	0.00077	0.00119	CcSEcCtD
Regadenoson—Pain—Bupropion—obesity	0.000762	0.00118	CcSEcCtD
Regadenoson—Asthenia—Orlistat—obesity	0.000758	0.00117	CcSEcCtD
Regadenoson—Hypersensitivity—Sibutramine—obesity	0.000753	0.00116	CcSEcCtD
Regadenoson—Eye disorder—Topiramate—obesity	0.000747	0.00115	CcSEcCtD
Regadenoson—Tinnitus—Topiramate—obesity	0.000745	0.00115	CcSEcCtD
Regadenoson—Cardiac disorder—Topiramate—obesity	0.000742	0.00114	CcSEcCtD
Regadenoson—Flushing—Topiramate—obesity	0.000742	0.00114	CcSEcCtD
Regadenoson—Feeling abnormal—Bupropion—obesity	0.000735	0.00113	CcSEcCtD
Regadenoson—Asthenia—Sibutramine—obesity	0.000734	0.00113	CcSEcCtD
Regadenoson—Gastrointestinal pain—Bupropion—obesity	0.000729	0.00112	CcSEcCtD
Regadenoson—Angiopathy—Topiramate—obesity	0.000725	0.00112	CcSEcCtD
Regadenoson—Diarrhoea—Orlistat—obesity	0.000723	0.00111	CcSEcCtD
Regadenoson—Immune system disorder—Topiramate—obesity	0.000722	0.00111	CcSEcCtD
Regadenoson—Mediastinal disorder—Topiramate—obesity	0.00072	0.00111	CcSEcCtD
Regadenoson—Urticaria—Bupropion—obesity	0.000708	0.00109	CcSEcCtD
Regadenoson—Abdominal pain—Bupropion—obesity	0.000705	0.00109	CcSEcCtD
Regadenoson—Mental disorder—Topiramate—obesity	0.0007	0.00108	CcSEcCtD
Regadenoson—Diarrhoea—Sibutramine—obesity	0.0007	0.00108	CcSEcCtD
Regadenoson—Dizziness—Orlistat—obesity	0.000699	0.00108	CcSEcCtD
Regadenoson—Erythema—Topiramate—obesity	0.000696	0.00107	CcSEcCtD
Regadenoson—Dysgeusia—Topiramate—obesity	0.000681	0.00105	CcSEcCtD
Regadenoson—Dizziness—Sibutramine—obesity	0.000676	0.00104	CcSEcCtD
Regadenoson—Vomiting—Orlistat—obesity	0.000672	0.00104	CcSEcCtD
Regadenoson—Rash—Orlistat—obesity	0.000666	0.00103	CcSEcCtD
Regadenoson—Dermatitis—Orlistat—obesity	0.000666	0.00103	CcSEcCtD
Regadenoson—Headache—Orlistat—obesity	0.000662	0.00102	CcSEcCtD
Regadenoson—Hypersensitivity—Bupropion—obesity	0.000657	0.00101	CcSEcCtD
Regadenoson—Vision blurred—Topiramate—obesity	0.000656	0.00101	CcSEcCtD
Regadenoson—Tremor—Topiramate—obesity	0.000652	0.00101	CcSEcCtD
Regadenoson—S-Adenosylmethionine—CYP2E1—obesity	0.00065	0.0269	CrCbGaD
Regadenoson—Vomiting—Sibutramine—obesity	0.00065	0.001	CcSEcCtD
Regadenoson—Ill-defined disorder—Topiramate—obesity	0.000646	0.000996	CcSEcCtD
Regadenoson—Rash—Sibutramine—obesity	0.000645	0.000994	CcSEcCtD
Regadenoson—Dermatitis—Sibutramine—obesity	0.000644	0.000993	CcSEcCtD
Regadenoson—Headache—Sibutramine—obesity	0.000641	0.000988	CcSEcCtD
Regadenoson—Asthenia—Bupropion—obesity	0.00064	0.000986	CcSEcCtD
Regadenoson—Nausea—Orlistat—obesity	0.000628	0.000968	CcSEcCtD
Regadenoson—Malaise—Topiramate—obesity	0.000628	0.000968	CcSEcCtD
Regadenoson—Syncope—Topiramate—obesity	0.000624	0.000962	CcSEcCtD
Regadenoson—Palpitations—Topiramate—obesity	0.000615	0.000948	CcSEcCtD
Regadenoson—Loss of consciousness—Topiramate—obesity	0.000612	0.000943	CcSEcCtD
Regadenoson—Diarrhoea—Bupropion—obesity	0.00061	0.000941	CcSEcCtD
Regadenoson—Nausea—Sibutramine—obesity	0.000607	0.000937	CcSEcCtD
Regadenoson—Cough—Topiramate—obesity	0.000607	0.000937	CcSEcCtD
Regadenoson—Convulsion—Topiramate—obesity	0.000603	0.00093	CcSEcCtD
Regadenoson—Hypertension—Topiramate—obesity	0.000601	0.000927	CcSEcCtD
Regadenoson—Chest pain—Topiramate—obesity	0.000592	0.000914	CcSEcCtD
Regadenoson—Arthralgia—Topiramate—obesity	0.000592	0.000914	CcSEcCtD
Regadenoson—Myalgia—Topiramate—obesity	0.000592	0.000914	CcSEcCtD
Regadenoson—Anxiety—Topiramate—obesity	0.00059	0.000911	CcSEcCtD
Regadenoson—Dizziness—Bupropion—obesity	0.00059	0.000909	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000588	0.000907	CcSEcCtD
Regadenoson—Discomfort—Topiramate—obesity	0.000585	0.000903	CcSEcCtD
Regadenoson—Vomiting—Bupropion—obesity	0.000567	0.000874	CcSEcCtD
Regadenoson—Rash—Bupropion—obesity	0.000562	0.000867	CcSEcCtD
Regadenoson—Dermatitis—Bupropion—obesity	0.000562	0.000866	CcSEcCtD
Regadenoson—Shock—Topiramate—obesity	0.000559	0.000862	CcSEcCtD
Regadenoson—Headache—Bupropion—obesity	0.000558	0.000861	CcSEcCtD
Regadenoson—Nervous system disorder—Topiramate—obesity	0.000557	0.000859	CcSEcCtD
Regadenoson—Tachycardia—Topiramate—obesity	0.000554	0.000855	CcSEcCtD
Regadenoson—Skin disorder—Topiramate—obesity	0.000552	0.000851	CcSEcCtD
Regadenoson—Hyperhidrosis—Topiramate—obesity	0.000549	0.000847	CcSEcCtD
Regadenoson—Hypotension—Topiramate—obesity	0.000531	0.000818	CcSEcCtD
Regadenoson—Nausea—Bupropion—obesity	0.00053	0.000817	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Topiramate—obesity	0.000517	0.000798	CcSEcCtD
Regadenoson—Insomnia—Topiramate—obesity	0.000514	0.000792	CcSEcCtD
Regadenoson—Paraesthesia—Topiramate—obesity	0.00051	0.000787	CcSEcCtD
Regadenoson—Dyspnoea—Topiramate—obesity	0.000506	0.000781	CcSEcCtD
Regadenoson—Somnolence—Topiramate—obesity	0.000505	0.000779	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Topiramate—obesity	0.00049	0.000756	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PRLH—obesity	0.000487	0.00149	CbGpPWpGaD
Regadenoson—Pain—Topiramate—obesity	0.000486	0.000749	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—obesity	0.000485	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—obesity	0.000483	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—obesity	0.000475	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPY1R—obesity	0.000474	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MC3R—obesity	0.000474	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MC4R—obesity	0.000474	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPY2R—obesity	0.000474	0.00145	CbGpPWpGaD
Regadenoson—Feeling abnormal—Topiramate—obesity	0.000468	0.000722	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CNR1—obesity	0.000467	0.00143	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Topiramate—obesity	0.000464	0.000716	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PPY—obesity	0.000464	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PRKCD—obesity	0.00046	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCH—obesity	0.000456	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GIP—obesity	0.000456	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—DRD2—obesity	0.000455	0.00139	CbGpPWpGaD
Regadenoson—Urticaria—Topiramate—obesity	0.000451	0.000696	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GCG—obesity	0.000451	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT2—obesity	0.000449	0.00137	CbGpPWpGaD
Regadenoson—Abdominal pain—Topiramate—obesity	0.000449	0.000692	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—obesity	0.000435	0.00133	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—obesity	0.000432	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS2—obesity	0.000428	0.00131	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB3—obesity	0.000427	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—obesity	0.000419	0.00128	CbGpPWpGaD
Regadenoson—Hypersensitivity—Topiramate—obesity	0.000418	0.000645	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—C3—obesity	0.000418	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GAL—obesity	0.000417	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—obesity	0.000415	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—C5AR1—obesity	0.000412	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RHOA—obesity	0.000412	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB2—obesity	0.000408	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3R1—obesity	0.000408	0.00124	CbGpPWpGaD
Regadenoson—Asthenia—Topiramate—obesity	0.000407	0.000628	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GHRH—obesity	0.000404	0.00123	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NMB—obesity	0.000404	0.00123	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—obesity	0.000397	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BAD—obesity	0.00039	0.00119	CbGpPWpGaD
Regadenoson—Diarrhoea—Topiramate—obesity	0.000389	0.000599	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GNB3—obesity	0.000388	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB3—obesity	0.000388	0.00118	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FFAR4—obesity	0.000385	0.00118	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GAL—obesity	0.000379	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNAS—obesity	0.000378	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCK—obesity	0.000377	0.00115	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—obesity	0.000376	0.00115	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—obesity	0.000376	0.00115	CbGpPWpGaD
Regadenoson—Dizziness—Topiramate—obesity	0.000376	0.000579	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—C5AR1—obesity	0.000374	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS1—obesity	0.000373	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHSR—obesity	0.000369	0.00113	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MCHR1—obesity	0.000369	0.00113	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRS3—obesity	0.000369	0.00113	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GLP1R—obesity	0.000367	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2—obesity	0.000367	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL5—obesity	0.000362	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCKAR—obesity	0.000361	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HRH3—obesity	0.000361	0.0011	CbGpPWpGaD
Regadenoson—Vomiting—Topiramate—obesity	0.000361	0.000557	CcSEcCtD
Regadenoson—Rash—Topiramate—obesity	0.000358	0.000552	CcSEcCtD
Regadenoson—Dermatitis—Topiramate—obesity	0.000358	0.000552	CcSEcCtD
Regadenoson—Headache—Topiramate—obesity	0.000356	0.000549	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKT2—obesity	0.000345	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRLHR—obesity	0.000343	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GH1—obesity	0.000343	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SH2B1—obesity	0.000343	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCK—obesity	0.000342	0.00105	CbGpPWpGaD
Regadenoson—Nausea—Topiramate—obesity	0.000337	0.00052	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—obesity	0.000334	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GLP1R—obesity	0.000334	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—obesity	0.000332	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCKAR—obesity	0.000328	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRH3—obesity	0.000328	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NPY—obesity	0.000327	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—obesity	0.000327	0.000999	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IAPP—obesity	0.000325	0.000994	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—MAPK8—obesity	0.000324	0.00099	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PYY—obesity	0.000323	0.000985	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APLN—obesity	0.000323	0.000985	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—TYK2—obesity	0.000319	0.000975	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR2A—obesity	0.000319	0.000974	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—C3—obesity	0.000318	0.000972	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RHOA—obesity	0.000317	0.000967	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKAR2B—obesity	0.000316	0.000965	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CRH—obesity	0.000316	0.000965	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR1B—obesity	0.000316	0.000965	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3R1—obesity	0.000313	0.000957	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PNLIP—obesity	0.000306	0.000934	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGT—obesity	0.000303	0.000924	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NPS—obesity	0.0003	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SDC3—obesity	0.000299	0.000912	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPY—obesity	0.000297	0.000908	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IAPP—obesity	0.000296	0.000903	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—DRD1—obesity	0.000294	0.000897	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR2C—obesity	0.000294	0.000897	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NMU—obesity	0.000292	0.000891	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PMCH—obesity	0.000292	0.000891	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HCRT—obesity	0.000292	0.000891	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY5R—obesity	0.000292	0.000891	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—obesity	0.000291	0.000888	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—obesity	0.000289	0.000884	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—obesity	0.000289	0.000884	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR1B—obesity	0.000287	0.000876	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CRH—obesity	0.000287	0.000876	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB1—obesity	0.000284	0.000869	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MC3R—obesity	0.00028	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY2R—obesity	0.00028	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY1R—obesity	0.00028	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MC4R—obesity	0.00028	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—F2—obesity	0.00028	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GHRL—obesity	0.000278	0.00085	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—DRD4—obesity	0.000276	0.000843	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PPY—obesity	0.000274	0.000838	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPS—obesity	0.000272	0.000831	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC8—obesity	0.000269	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GIP—obesity	0.000269	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCH—obesity	0.000269	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—DRD1—obesity	0.000267	0.000815	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR2C—obesity	0.000267	0.000815	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR1—obesity	0.000264	0.000805	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB1—obesity	0.000258	0.000789	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—DRD2—obesity	0.000257	0.000786	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEPR—obesity	0.000256	0.000781	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GCG—obesity	0.000255	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—obesity	0.000255	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GHRL—obesity	0.000253	0.000772	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—DRD4—obesity	0.000251	0.000766	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL2—obesity	0.000249	0.000761	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK8—obesity	0.000245	0.000747	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CNR1—obesity	0.000239	0.000731	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—DRD2—obesity	0.000234	0.000714	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GCG—obesity	0.000231	0.000706	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB2—obesity	0.00023	0.000704	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—obesity	0.000229	0.0007	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB3—obesity	0.000229	0.000699	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GAL—obesity	0.000224	0.000683	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—obesity	0.000224	0.000683	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—C5AR1—obesity	0.000221	0.000675	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNB3—obesity	0.00022	0.00067	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNAS—obesity	0.000214	0.000653	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB2—obesity	0.000209	0.000639	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—obesity	0.000207	0.000633	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCL5—obesity	0.000204	0.000624	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—obesity	0.000203	0.00062	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKG1—obesity	0.000202	0.000618	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCK—obesity	0.000202	0.000618	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNB3—obesity	0.000199	0.000609	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RBP4—obesity	0.000197	0.000602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GLP1R—obesity	0.000197	0.000602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNAS—obesity	0.000194	0.000593	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCKAR—obesity	0.000194	0.000592	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRH3—obesity	0.000194	0.000592	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—obesity	0.000187	0.000572	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKAR2B—obesity	0.000187	0.00057	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL5—obesity	0.000186	0.000567	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCD—obesity	0.000184	0.000562	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCF2—obesity	0.00018	0.000551	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR2A—obesity	0.00018	0.00055	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—C3—obesity	0.00018	0.00055	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—obesity	0.000176	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY—obesity	0.000176	0.000537	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOC3—obesity	0.000175	0.000533	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IAPP—obesity	0.000175	0.000533	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGT—obesity	0.000171	0.000522	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRH—obesity	0.000169	0.000518	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR1B—obesity	0.000169	0.000518	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SDC1—obesity	0.000168	0.000512	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCD—obesity	0.000167	0.000511	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C3—obesity	0.000165	0.000504	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR2A—obesity	0.000164	0.0005	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—C3—obesity	0.000163	0.000499	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPS—obesity	0.000161	0.000491	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2—obesity	0.000158	0.000482	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCB—obesity	0.000158	0.000482	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DRD1—obesity	0.000158	0.000481	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR2C—obesity	0.000158	0.000481	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—obesity	0.000156	0.000477	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGT—obesity	0.000155	0.000474	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NTRK2—obesity	0.000153	0.000468	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB1—obesity	0.000153	0.000466	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—obesity	0.000151	0.000462	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PARP1—obesity	0.000149	0.000456	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHRL—obesity	0.000149	0.000456	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DRD4—obesity	0.000148	0.000452	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—obesity	0.000144	0.00044	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—obesity	0.000144	0.00044	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—F2—obesity	0.000143	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCB—obesity	0.000143	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR1—obesity	0.000141	0.000432	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TCF7L2—obesity	0.000139	0.000424	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT2—obesity	0.000138	0.000422	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DRD2—obesity	0.000138	0.000422	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—obesity	0.000137	0.000419	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN1—obesity	0.000137	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GCG—obesity	0.000137	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—obesity	0.000133	0.000406	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—obesity	0.000131	0.000399	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRL—obesity	0.00013	0.000398	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STK11—obesity	0.000128	0.000392	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL2—obesity	0.000128	0.000391	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLG—obesity	0.000127	0.000388	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RHOA—obesity	0.000127	0.000387	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT2—obesity	0.000126	0.000384	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3R1—obesity	0.000126	0.000383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FOXO3—obesity	0.000124	0.000379	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB2—obesity	0.000124	0.000378	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOCS1—obesity	0.000122	0.000372	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—obesity	0.000121	0.000369	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOCS3—obesity	0.00012	0.000367	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNB3—obesity	0.000118	0.00036	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—TYK2—obesity	0.000116	0.000355	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—obesity	0.000116	0.000354	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF2—obesity	0.000116	0.000353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RHOA—obesity	0.000115	0.000352	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNAS—obesity	0.000115	0.00035	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3R1—obesity	0.000114	0.000348	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOB—obesity	0.000112	0.000343	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL5—obesity	0.00011	0.000335	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LPL—obesity	0.000107	0.000327	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FOXO1—obesity	0.000106	0.000325	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RPS6KB1—obesity	0.000106	0.000325	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—obesity	0.000105	0.000321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCD—obesity	9.88e-05	0.000302	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR2A—obesity	9.67e-05	0.000295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—C3—obesity	9.65e-05	0.000295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS2—obesity	9.18e-05	0.00028	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGT—obesity	9.17e-05	0.00028	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—obesity	8.99e-05	0.000274	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOE—obesity	8.99e-05	0.000274	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—obesity	8.9e-05	0.000272	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA1—obesity	8.88e-05	0.000271	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—obesity	8.58e-05	0.000262	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2—obesity	8.47e-05	0.000259	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCB—obesity	8.47e-05	0.000259	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BAD—obesity	8.37e-05	0.000256	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—obesity	8.11e-05	0.000248	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS1—obesity	8.02e-05	0.000245	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—obesity	7.72e-05	0.000236	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INS—obesity	7.68e-05	0.000234	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL2—obesity	7.55e-05	0.000231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—obesity	7.43e-05	0.000227	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT2—obesity	7.42e-05	0.000227	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—obesity	7.13e-05	0.000218	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—obesity	7.06e-05	0.000216	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—obesity	7.05e-05	0.000215	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TYK2—obesity	6.86e-05	0.000209	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RHOA—obesity	6.8e-05	0.000208	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—obesity	6.73e-05	0.000206	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3R1—obesity	6.73e-05	0.000206	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—obesity	6.41e-05	0.000196	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—obesity	6.21e-05	0.00019	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—obesity	6.21e-05	0.00019	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—obesity	5.77e-05	0.000176	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—obesity	5.68e-05	0.000173	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—obesity	5.4e-05	0.000165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK8—obesity	5.25e-05	0.00016	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—obesity	5.24e-05	0.00016	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—obesity	4.8e-05	0.000147	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—obesity	4.46e-05	0.000136	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—obesity	4.45e-05	0.000136	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—obesity	3.79e-05	0.000116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—obesity	3.35e-05	0.000102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—obesity	3.09e-05	9.45e-05	CbGpPWpGaD
